China Biologic Products (CBPO) Announces Shareholders' Approval of Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Nasdaq outshines Wall St peers on tech boost, earnings glee
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
China Biologic Announces Shareholders' Approval of Merger Agreement
March 1, 2021 8:00 AM ESTBEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as... More
